Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL791741 | 0.82 | VEGFA (0.50) | ALDH1A1KDM4EMEN1KMT2AHIF1A | |
| SCHEMBL14498226 | 0.77 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3SOS1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5037785 | 0.77 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3SOS1ALDH1A1 | |
| SCHEMBL2779198 | 0.75 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3SOS1ALDH1A1 | |
| SCHEMBL14044360 | 0.75 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3SOS1ALDH1A1 | |
| SCHEMBL27978884 | 0.75 | SLC6A4 (0.52) | SLC6A2SLC6A4SLC6A3SOS1MEN1 | |
| SCHEMBL70402 | 0.75 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3SOS1ALDH1A1 | |
| SCHEMBL14434127 | 0.75 | KDM4E (0.41) | SLC6A2SLC6A4SLC6A3SOS1ALDH1A1 | |
| SCHEMBL13476626 | 0.75 | ALDH1A1 (0.43) | ALDH1A1KDM4EMEN1KMT2AHIF1A | |
| SCHEMBL21088501 | 0.74 | KDM1A (0.40) | ALDH1A1KDM4EMEN1KMT2AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172270-A1 | 2-'4(PHENYLAMINO)-PIPERIDIN-1-YL!-N-PHENYL-ACETAMINE DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5 (NPY5) LIGANDS FOR THE TREATMENT OF OBESITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2011-07-14 | — | — | US | disclosed |
| US-7888510-B2 | 1,4-disubstituted piperidine compounds like N-(9-Ethyl-9H-carbazol-3-yl)-2-[4-(2-hydroxymethyl-6-methyl-phenylamino)-piperidine-yl]acetamide; chloroacetyl chloride is reacted with respective compounds in the presence of dichloromethane and triethylamine or diisopropylethylamine | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2011-02-15 | — | — | US | disclosed |
| EP-1660131-B1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | ESTEVE LABOR DR (ES) | 2009-06-24 | — | — | EP | disclosed |
| US-20080119516-A1 | 2-'4(Phenylamino)-Piperidin-1-Yl!-N-Phenyl-Acetamine Derivatives and Related Compounds as Neuropeptide Y5 (NPY5) Ligands for the Treatment of Obesity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-05-22 | — | — | US | disclosed |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-01-11 | — | — | US | disclosed |
| EP-1648458-B1 | 2-[4(PHENYLAMINO)-PIPERIDIN-1-YL]-N-PHENYL-ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5 (NPY5) LIGANDS FOR THE TREATEMENT OF OBESITY | ESTEVE LABOR DR (ES) | 2006-12-20 | — | — | EP | disclosed |
| EP-1660131-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-05-31 | — | — | EP | disclosed |
| EP-1648458-A1 | 2-'4(PHENYLAMINO)-PIPERIDIN-1-YL]-N-PHENYL-ACETAMINE DERIVTIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5 (NPY5) LIGANDS FOR THE TREATEMENT OF OBESITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005013988-A1 | 2-`4(PHENYLAMINO)-PIPERIDIN-1-YL!-N-PHENYL-ACETAMINE DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5 (NPY5) LIGANDS FOR THE TREATEMENT OF OBESITY | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005014045-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119516-A1 | 2-'4(Phenylamino)-Piperidin-1-Yl!-N-Phenyl-Acetamine Derivatives and Related Compounds as Neuropeptide Y5 (NPY5) Ligands for the Treatment of Obesity | NPY5R, NPY1R, NPY4R | SLC6A2 1627/4885SLC6A4 939/4885SLC6A3 3137/4885 |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | NPY5R, HTR6, NPY2R | SLC6A2 125/4885SLC6A4 48/4885SLC6A3 144/4885 |
| US-20110172270-A1 | 2-'4(PHENYLAMINO)-PIPERIDIN-1-YL!-N-PHENYL-ACETAMINE DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5 (NPY5) LIGANDS FOR THE TREATMENT OF OBESITY | NPY5R, NPY1R, NPY4R | SLC6A2 1712/4885SLC6A4 965/4885SLC6A3 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.